OptiBiotix Health plc
("OptiBiotix" or the "Company")
New patent filing: Combination ingredients to reduce cardiovascular risk factors
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol,
diabetes and skin care, is pleased to announce a new patent filing. The filing protects the combination of OptiBiotix's Lactobacillus plantarum strain along with other ingredients identified by scientific key opinion leaders which act synergistically to reduce cardiovascular risk factors.
The patent filing follows on from the announcement on the 7 April 2016 relating to human studies which demonstrated 0.1g of a capsulated product has commercial potential as a safe, easy to use, low cost cholesterol reducing supplement. The filing of this patent extends OptiBiotix's protection across a broader range of market opportunities and increases the number of partnering opportunities.
Current products for cardiovascular disease tend to focus on single risk factors, largely LDL (bad) cholesterol. However, there is a growing evidence base that suggests cardiovascular risk is a sum of a number of factors including triglycerides and blood pressure.
The novelty in the new patent filing is that when used in combination with OptiBiotix's cholesterol reducing strain the combination has the potential to:-
i. Reduce multiple cardiovascular risk factors in a single presentation
ii. Enhance the overall effect on LDL reduction based on synergies in mechanism of action
iii. Reduce statin dosage mitigating possible side effects and improving patient compliance
The Company believes that filing this patent adds a further layer of protection to its intellectual property portfolio, creates a valuable asset, and broadens the number of product and partnering opportunities which now expands from consumer health to pharma.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the filing of this patent which adds a further level of protection and value to our cholesterol and blood pressure reducing product. Given the scale of the market opportunity in cardiovascular health and the limitations of existing products, combining our safe and efficacious product with existing treatments significantly broadens the commercial opportunity for OptiBiotix. Commercial discussions will continue with potential partners across both consumer and pharma to fully exploit the opportunity as a cholesterol and/or hypertension supplement, in isolation, or in combination with existing approaches."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
OptiBiotix Health plc |
www.optibiotix.com |
Stephen O'Hara, Chief Executive |
Contact via Walbrook below |
|
|
Cairn Financial Advisers LLP |
Tel: 020 7148 7900 |
Liam Murray |
|
|
|
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3764 2341 |
Peterhouse Corporate Finance Ltd (Joint Broker) |
|
Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or [email protected] |
Anna Dunphy |
Mob: 07876 741 001 |
Mike Wort |
Mob: 07900 608 002 |
About OptiBiotix Health plc - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
